Understand the source comparison
SLU-PP-332 Oral vs Subcutaneous Administration Comparison
Oral <2% Gastric acid (pH 1.5–3.5) denatures structure; pepsin, trypsin, chymotrypsin cleave peptide bonds; first-pass hepatic metabolism eliminates remaining intact molecules N/A. Insufficient systemic absorption Not viable Oral delivery results in complete l
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Oral
- <2%
- Gastric acid (pH 1.5–3.5) denatures structure; pepsin, trypsin, chymotrypsin cleave peptide bonds; first-pass hepatic metabolism eliminates remaining intact molecules
- N/A. Insufficient systemic absorption
- Not viable
- Oral delivery results in complete loss of pharmacological activity. The compound never reaches target tissues in functional form.
- Subcutaneous
- 85–92%
- Minimal. Bypasses GI tract and first-pass metabolism; enzymatic degradation occurs only after systemic circulation
- 45–90 minutes post-injection
- Standard method for research peptides
- Subcutaneous route is the only pharmacologically viable administration method. Proper reconstitution and storage are critical to maintain bioavailability.
- Intravenous
- ~98%
- Minimal. Enters circulation directly
- Immediate (within 2–5 minutes)
- Rarely used outside clinical settings due to administration complexity
- Highest bioavailability but impractical for most research protocols. Offers no meaningful advantage over subcutaneous for sustained-release peptides like SLU-PP-332.